Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. FIX
8. BE
9. AXP
10. NDAQ

Go back to Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 6c

Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019 4:01 PM EDT

Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2019 and provided a corporate update.

Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make significant progress advancing our... More